South Korean Investors Led Foreign Purchases of U.S. Stocks in 2025, Data Shows
South Korean investors emerged as the top foreign purchasers of U.S. stocks from January to November 2025, acquiring nearly five times more than in 2024. This trend persisted despite strong performance by the domestic Kospi index. Government tax breaks aim to redirect investments domestically, but outflows continued into early 2026.
Substrate placeholder — needs review · Wikimedia Commons (CC BY-SA 3.0)U.S. stocks among foreign buyers from January to November 2025, according to data reported by CNBC. S. stocks in 2025 than in 2024, even as South Korea's benchmark Kospi stock index delivered 75% returns in 2024 and hit new highs in 2025.
S. 8% for emerging economies, as detailed in a Bank of Korea report released last week. South Korea has about 15 million retail investors, who account for 60% to 70% of annual trading volume, according to GAM Investments.
U.S. equities by South Korean retail investors exceeded total net overseas purchases, based on data from the Korea Securities Depository. The South Korean government announced tax breaks for individual investors who sell foreign holdings, exempting taxes on capital gains from overseas stocks if the proceeds are invested in domestic stocks for one year, subject to certain conditions.
U.S. stocks at almost $10 billion, excluding the Cayman Islands and Ireland. The S&P 500 outperformed the Kospi in four of the past five years, though the Kospi outperformed the S&P 500 and Nasdaq in 2025.
South Korean individual investors' investment in foreign assets in 2025 was more than tripled, or almost four times higher, compared to 2020, according to Kang Min Joo. S. market attractiveness. S. market investment.
U.S. market, which provided higher returns. Florian Weidinger, CEO at Santa Lucia Asset Management, told CNBC that while recent efforts in South Korea attempt to create a stronger domestic equity culture that encourages wealth creation away from the property market, locals don't seem convinced.
U.S. equities. S. are seen as more shareholder-friendly and transparent, with a track record of rewarding investors through dividends and buybacks, and stronger corporate governance compared to South Korean firms, according to the CNBC report.
Key Facts
Story Timeline
5 events- 2026-01-01 to 2026-02-28
South Korea was the largest net buyer of U.S. stocks at almost $10 billion, excluding the Cayman Islands and Ireland.
1 sourceCNBC - 2026-04-17 (approx., last week from 2026-04-24)
Bank of Korea released a report on external portfolio shares.
1 sourceCNBC - 2025-01-01 to 2025-11-30
South Korean investors were the largest foreign buyers of U.S. stocks.
1 sourceCNBC - 2024-12-01 (approx.)
South Korean government announced tax break measures.
1 sourceCNBC - 2024-01-01 to 2024-12-31
Kospi stock index delivered 75% returns.
1 sourceCNBC
Potential Impact
- 01
Increased exposure of South Korean investors to U.S. market volatility.
- 02
Potential reduction in domestic market liquidity if outflows persist despite tax breaks.
- 03
Short-term boost to Kospi if tax measures encourage reinvestment.
- 04
Sustained appeal of U.S. equities could pressure South Korean firms to improve governance.
Transparency Panel
Related Stories
rte.ieOil Prices Fall More Than 12% on Reports of US-Iran Deal
Reports indicate the United States and Iran are close to a 14-point memorandum of understanding to conclude the ongoing conflict. Oil prices fell sharply after the news emerged before partially recovering following an Iranian announcement. President Donald J. Trump stated that co…
Restaurant Brands International Reports Q1 2026 Earnings
Restaurant Brands International posted first-quarter adjusted earnings per share of 86 cents and revenue of $2.26 billion. Both figures exceeded Wall Street forecasts. Net income attributable to common shareholders reached $338 million.
White House Projects $529 Billion in Potential Savings Over Decade From Trump-Era Drug Pricing Policy
White House economists projected $529 billion in savings over the next decade from agreements President Donald Trump reached with pharmaceutical companies. The analysis also forecasts $64.3 billion in Medicaid savings and up to $733 billion if the framework expands.